ECONOMY OF FOREIGN COUNTRIES УДК 330.341:336.5:338.45 JEL: L52, L65, O14, O32 SALIKHOVA Olena1, HONCHARENKO Daria2 1Institute for Economics and Forecasting of the NAS of Ukraine, Research ID : http://www.researcherid.com/rid/ DEVELOPMENT OF THE PHARMACEUTICAL INDUSTRY IN POLAND IN THE CONTEXT OF NEW OPPORTUNITIES AND CHALLENGES OF EUROPEAN INTEGRATION: CONCLUSIONS FOR UKRAINE In the short term, the measures of the Polish government in the process of European integration proved to be ineffective and did not allow to achieve the goal set by 2002: to strengthen the competitiveness of pharmaceutical companies. The implementation of EU standards and regulations, the adoption of the law on forms of support for innovation have created the basis for the government (co-financed by EU funds) to support research and development and innovation projects and launch the sectoral program InnoNeuroPharm, which, together with tax incentives for research and development and other activities politicians, gave positive impetus to business. With the accession to the EU, Polish pharmaceutical manufacturers have improved their economic results, but still lag far behind German manufacturers, in terms of both technological level and innovation activity, as well as in terms of productivity and wages. The development of the industry is hampered by a number of obstacles: lack of a clear strategy and lack of coordination between concerned authorities; lack of incentives to attract investment; human factor and “industrial corruption”. In the process of European integration, Poland quickly managed to introduce top-down formal institutions, but the transformation of informal institutions continues today. One of the factors that caused falling behind and weak competitiveness of Ukrainian medicines is that European integration processes are aimed primarily at harmonizing the legislative and regulatory framework for pharmaceuticals production, rather than building the potential for endogenous development of the industry. It is noted that only the introduction of a purposeful comprehensive state policy of building "technological champions" in pharmaceuticals based on endogenous innovations can “convert” European integration processes into competitive Ukrainian products and bring them to European markets. It is substantiated that without mental and value changes, transformation of informal institutions and improvement of framework conditions for innovations, the country's benefits from European integration for the development of Ukrainian pharmaceuticals will be limited and unable to reduce the technological and economic gap with European industry leaders. Keywords:Poland; public policy; European integration; pharmaceutics; innovations; technological development.
1. Salikhova O., Honcharenko D. Development policy of the pharmaceutical industry in Germany: Lessons for Ukraine. Economy of Ukraine, 2020, No. 10, pp. 63-83 [in Ukrainian]. doi.org/10.15407/economyukr.2020.10.063 2. De Ruyt J., Vos S., Kovanda K. Poland under scrutiny in the European Union. Covington, January 27, 2016, available at: www.globalpolicywatch.com/2016/01/poland-under-scrutiny-in-the-european-union/ (accessed on: 25.03.2021). 3. Morawski I. Wpływ integracji europejskiej na polską gospodarkę, in: 15 lat Polski w Unii Europejskiej. Raport pod red. Anny Radwan-Röhrenschef. Instytut In.Europa. Warszawa, 2019, available at: ineuropa.pl/in15/wplyw-integracji-europejskiej/ [in Polish]. 4. Przybyliński M., Świeczewska I., Trębska J., Gorzałczyński A. Makroekonomiczny wpływ sektora farmaceutycznego na polską gospodarkę. Łódź, Krajowi Producenci Leków, 2020 [in Polish]. 5. Fedyaeva M. Development of regulatory policy of the state in the context of European integration processes in the national economy. Classic Private University, Zaporizhzhia, 2015 [in Ukrainian]. 6. Sidenko V. The Crisis processes in the EU development: origins and prospects. Economy and Forecasting, 2017, No. 1, pp. 7-30. doi.org/10.15407/eip2017.01.007 7. Lagutin V. Effects of the state regulation of economy in conditions of the European integration of Ukraine. Foreign Trade: Economics, Finance, Law, 2017, No. 6, pp. 5-23 [in Ukrainian]. 8. Pashkov V. Legal Regulation of the Implementation of the EU Legislation in the Field of Medicines Circulation. Medical Law, 2016, No. 2, pp. 55-62 [in Ukrainian]. doi.org/10.25040/medicallaw2016.02.055 9. Nikityuk V., Shikina T. Pharmaceutical industry of Ukraine -- integration into the European and world market or stalling? APTEKA online. 2019, No. 1, August 12, available at: www.apteka.ua/article/510294 [in Ukrainian]. 10. Salikhova O., Honcharenko D. Endogenization of Economic Development through the Development of High-Tech Pharmaceutical Industries: Europe's Experience, Lessons for Ukraine. Business Inform, 2020, No. 2, pp. 49-56 [in Ukrainian]. doi.org/10.32983/2222-4459-2020-2-49-56 11. Salikhova O., Goncharenko D. The pharmaceutical industry of France. Foreign Trade: Economics, Finance, Law, 2020, No. 2, pp. 67-85 [in Ukrainian]. doi.org/10.31617/zt.knute.2020(109)05 12. Filipchuk V., Povoroznyk V., Bochi A., Yaroshenko E. Free Trade Zone with the EU: A Unique Chance or Lost Opportunities? Kyiv, International Centre for Policy Studies, 2015 [in Ukrainian]. 13. Implementation of the Association Agreement between Ukraine and the EU: economic challenges and new opportunities. V.M. Heyets, T.O. Ostashko (Eds.). NAS of Ukraine, Institute for Economics and Forecasting of the NAS of Ukraine, Kyiv, 2016 [in Ukrainian]. 14. Kikta T. Przemysł farmaceutyczny w Polsce (1823-1939). Warszawa, Państwowy Zakład Wydawn, Lekarskich, 1972 [in Polish]. 15. Pikos A. Continuity of Narratives: Reinterpretations of Polish Business History. Central Europe Management Journal, 2018, Vol. 26, Iss. 4, pp. 47-63 [in Polish]. doi.org/10.7206/jmba.ce.2450-7814.242 16. Zagrosik M. Prawo do świadczeń zdrowotnych po wprowadzeniu powszechnego ubezpieczenia zdrowotnego. Prawo i Medycyna, 1999, Vol. 1, Iss. 1, pp. 13-27 [in Polish]. 17. Doliwa-Klepacki Z. Integracja Europejska (po zakończeniu negocjacji Polski z UE). Białystok, 2003, available at: repozytorium.uwb.edu.pl/jspui/bitstream/11320/7253/1/ZM_Doliwa-Klepacki_Integracja_europejska.pdf [in Polish]. 18. Tyszka A., Lubos В. Innowacje w sektorze farmaceutycznym w Polsce. International Journal of Management and Economics, 2008, Vol. 24, pp. 221-235 [in Polish]. 19. Jasiński A. Instrumenty polityki innowacyjnej: Czy grają w Polsce? Zagadnienia Naukoznawstwa, 2013, Vol. 1 (195), pp. 3-23 [in Polish]. 20. Salikhova O., Honcharenko D. Endogenization of Economic Development through the Development of High-Tech Pharmaceutical Industries: Europe's Experience, Lessons for Ukraine. Business Inform, 2020, No. 2, pp. 49-56 [in Ukrainian]. doi.org/10.32983/2222-4459-2020-2-49-56 21. Żakowiecki P. Zdrowy przemysł Reindustrializacja krajowej branży farmaceutycznej. POLITYKA INSIGHT, Polski Związek Pracodawców Przemysłu Farmaceutycznego, available at: www.producencilekow.pl/wp-content/uploads/2017/11/PI-Research-Zdrowy-przemys%C5%82.pdf [in Polish]. 22. Misiurewicz-Gabi A. Refundacyjny Tryb Rozwojowy -- czy ktoś da mu szansę? Termedia, February 8, 2020, available at: www.termedia.pl/mz/Refundacyjny-Tryb-Rozwojowy-czy-ktos-da-mu-szanse-,36839.html [in Polish]. 23. Salikhova O., Honcharenko D. Ukraine's pharmaceuticals: From dependence to endogenous development. Economy and Forecasting, 2020, No. 4, pp. 7-35 [in Ukrainian]. doi.org/10.15407/econforecast2020.04.005 24. Salikhova O. High-tech capital goods in import structure of Ukraine. Economist, 2011, No. 9, pp. 28-32 [in Ukrainian]. 25. Honcharenko D. New Approaches to the Assessment of Foreign Trade in High-Tech Pharmaceuticals. Statistics of Ukraine, 2020, No. 1, pp. 35-41. doi.org/10.31767/su.1(88)2020.01.04 26. Młynarek M. Zjawiska patologiczne na rynku farmaceutycznym mgr farm. Instytut Wymiaru Sprawiedliwości, Prawo karne i kryminologia, Warszawa, 2019 [in Polish]. 27. Polak P. Nowe formy korupcji: analiza socjologiczna sektora farmaceutycznego w Polsce. Kraków, Nomos, 2011 [in Polish]. 28. Góra K., Jagliński K. Suwerenność lekowa państwa - rola, stan i rekomendacje. Raport Fundacji Republikańskiej, May, 2020, available at: www.producencilekow.pl/wp-content/uploads/2020/06/Suwerenność-lekowa-państwa.-Rola-stan-i-perspektywy.pdf [in Polish]. 29. Bentkowska K. Przemiany instytucjonalne w Polsce - proces zakończony czy nieustające wyzwanie? Trzydziestolecie restytucji kapitalizmu w Polsce, R. Michalski (Ed.). Warszawa, 2019, pp. 39-63, available at: cor.sgh.waw.pl/handle/20.500.12182/859 [in Polish]. 30. Salikhova O. Germany's industrial leadership: View of the role of the state in the historical and economic aspect. History of Economics and Economic Thought of Ukraine, 2020, Iss. 53, pp. 163-185, available at: ingedu.org.ua/docs/IN_2020_53_189.pdf [in Ukrainian]. doi.org/10.15407/ingedu2020.53.189 31. Salikhova O., Honcharenko D. Policy of endogenous development of pharmaceuticals in China: Lessons for Ukraine. Economy and Forecasting, 2020, No. 2, pp. 139-157 [in Ukrainian]. doi.org/10.15407/eip2020.02.139 32. Honcharenko D. The Pharmaceutical Industry in New EU Member States: A Statistical Comparison with Germany. Lessons for Ukraine. Statistics of Ukraine, 2021, No. 2, pp. 26-38. 33. Salikhova O., Honcharenko D. The Conceptual Foundations of the Strategy of Development of the High-Tech Industry of Pharmaceuticals and Medical Products in Ukraine till 2030. Business Inform, 2020, No. 7, pp. 28-35 [in Ukrainian]. doi.org/10.32983/2222-4459-2020-7-28-35 34. Kostyuk G., Margitych V. On the national strategy of medical drug supply in Ukraine. Mirror Weekly, January 20, 2017, available at: zn.ua/ukr/promyshliennost/pro-nacionalnu-strategiyu-zabezpechennya-likami-v-ukrayini-_.html [in Ukrainian]. 35. Salikhova O., Krekhivsky O. A New Mechanism for State Support to Technological Innovation for Industrial Development. Statistics of Ukraine, 2018, No. 2, pp. 30-35 [in Ukrainian]. doi.org/10.31767/su.2(81)2018.02.04 36. Kindzers'kyi Yu. Anti-crisis industrial policy: Version of domestic concept. Visnyk of the NAS of Ukraine, 2016, No. 10, pp. 27-42 [in Ukrainian]. doi.org/10.15407/visn2016.10.027 |
|
Published since September 1958 |
|||
| Login |
| |||